logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

On May 6th, China Hongqiao Group spent HK$47.9684 million to repurchase 3.442 million shares.

date
07/05/2025
The Zhimedia Financial APP reported that China Hongqiao (01378.HK) announced on May 6, 2025 that the company would spend 47.9684 million Hong Kong dollars to repurchase 3.442 million shares.
Latest
2 m ago
Taiwan side: No sovereign wealth fund should receive funds without compensation from foreign exchange reserves.
3 m ago
Hong Kong Innovation and Technology Bureau Director Sun Dong: Over 12,000 government officials use the local large-scale language model "Hong Wen Tong".
4 m ago
Yan Yuejin, deputy director of the Shanghai E-House Real Estate Research Institute: There will be further room for relaxation of personal mortgage loan policies.
4 m ago
The Hang Seng China index has erased earlier gains of 2.4%.
4 m ago
Goldman Sachs released a research report stating that Fosun Pharma's first-quarter sales were below the bank's expectations and further declined compared to the same quarter last year, mainly due to price reductions in contract renewals for centralized procurement and expansion of regional centralized procurement, leading to a year-on-year drop in pharmaceutical sales of about 10%. Although the growth in sales of new drugs partially mitigated the impact. The medical device business was driven by a 23% increase in sales of ventilators, but faced pressure in the weak consumption environment for medical beauty equipment and diagnostic reagents. The service business decreased by 2% year-on-year due to the termination of some online businesses, but achieved growth in offline businesses as the rehabilitation business expanded. The bank's outlook for the company's revenue this year is relatively conservative, expecting a 4% annual decline. Considering the lack of product cycle highlights, lack of significant growth drivers, and potential pressure from centralized procurement of biosimilars, profitability may depend on divestment of assets. The bank lowered its profit forecast for the company this year by 8.9%, and by 0.4% and 0.9% for next year and the following year. The target price was lowered from HK$17.27 to HK$16.38, maintaining a "neutral" rating.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.